Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Arena Pharmaceuticals, Smart & Final Stores, and Tilray Jumped Today

By Dan Caplinger - Nov 15, 2018 at 4:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Smart strategic moves helped these stocks gain ground.

The stock market stayed turbulent on Thursday, but the pattern was the reverse of what investors have had to deal with recently. Today, major benchmarks started the session on the downside, but positive comments about the likely pace of future interest rate increases from the Federal Reserve reassured investors that the curtain isn't yet falling on the bull market. Some individual companies also had good news that sent their shares sharply higher, and Arena Pharmaceuticals ( ARNA -6.81% ), Smart & Final Stores ( SFS ), and Tilray ( TLRY ) were among the best performers on the day. Here's why they did so well.

Arena makes a sale

Shares of Arena Pharmaceuticals soared 22% after the pharmaceutical company chose to make a strategic move with one of its key treatment prospects. Arena decided to enter into a licensing agreement with United Therapeutics ( UTHR -1.74% ) under which United will license pulmonary arterial hypertension candidate treatment ralinepag from Arena in exchange for an $800 million up-front cash payment. Arena will also have the right to receive $400 million in future milestone payments as well as tiered royalties in the low double-digit percentages, while United will have exclusive worldwide rights to the drug. With ralinepag in phase 3 trials, the move is a bet by United on the drug's future success, and Arena locks in a nice payday regardless of what happens in clinical trials while still retaining a stake if ralinepag turns into a big hit.

Woman in white lab coat holding clipboard in front of shelves of prescription drug bottles and containers.

Image source: Getty Images.

Smart & Final overcomes obstacles

Smart & Final Stores stock jumped 35% in the wake of the company's release of its third-quarter financial results. The discount retailer reported a small rise in comparable-store sales that helped push overall revenue higher by nearly 3%, and adjusted net income increased more than 30% from year-earlier levels. CEO David Hirz noted that the growth occurred "despite greater pressure from deflation in product prices," and Smart & Final is working harder than ever to build out its digital commerce capabilities to keep up with competitors. With the company having made substantial progress in paying down debt, investors are hopeful that Smart & Final can keep building positive momentum.

Tilray heads higher

Finally, shares of Tilray finished up 5%. The cannabis company got comments from stock analysts at Cowen that investors took as being positive, focusing on statements saying that Tilray's efforts to build recognizable brands and use consumer data effectively should pay off in the long run. Cowen merely maintained its outperform rating on the stock and actually cut its price target by $22 per share to $150, but the analyst company is still optimistic that the cannabis player's global scope makes Tilray a smart long-term play in the marijuana industry even if near-term results aren't quite as good as shareholders have hoped.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
ARNA
$49.55 (-6.81%) $-3.62
Smart & Final Stores, Inc. Stock Quote
Smart & Final Stores, Inc.
SFS
Tilray Stock Quote
Tilray
TLRY
United Therapeutics Corporation Stock Quote
United Therapeutics Corporation
UTHR
$185.99 (-1.74%) $-3.30

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.